All Stories
Subscribe to Medigene AG

Medigene AG

euro adhoc: MediGene AG
MediGene and Yamanouchi Conclude Marketing and Development Partnership For Anti-Cancer Drug Leuprogel® (New Name: Eligard®) (E)

  Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
Martinsried - San Diego, January 14, 2004. The German-American
biotechnology company MediGene AG (Frankfurt, Prime Standard: MDG)
has concluded a partnership with the pharmaceuticals group Yamanouchi
for the commercialization in Europe of the anti-cancer drug Eligard®,
previously known as Leuprogel®. Yamanouchi, the second largest
pharmaceuticals company in Europe in the field of urology, will take
on pan-European promotion and sale of the drug for the treatment of
prostate cancer. In return MediGene will receive successive milestone
payments totaling up to EUR23.5 million including a signing fee of
EUR4 million, as well as royalties on sales of Eligard®.
At the beginning of December 2003, the one-month sustained release
product of Leuprogel® / Eligard® received marketing authorization for
Germany. The three-months product is still undergoing approval
procedure by the German regulatory authorities. In April 2001,
MediGene had acquired the license for Leuprogel® / Eligard®  from the
US company Atrix Laboratories, Inc.
MediGene AG, e-mail:, Fax:	++ 49 - 89 - 85 65 -
Julia Hofmann, Public Relations	, Phone: ++ 49 - 89 - 85 65 - 3324
Dr. Michael Nettersheim, Investor Relations, Phone: ++ 49 - 89 - 85
65 - 2946
end of announcement        euro adhoc 14.01.2004

Further inquiry note:

Julia Hofmann
Tel.: +49 (0)89 8565 3324

Branche: Biotechnology
ISIN: DE0005020903
WKN: 502090
Index: CDAX, Prime All Share, Prime Standard, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Niedersächsische Börse zu Hannover / free trade
Berliner Wertpapierbörse / free trade
Bayerische Börse / free trade
Hamburger Wertpapierbörse / free trade
Bremer Wertpapierbörse (BWB) / free trade
Börse Düsseldorf / free trade
Baden-Württembergische Wertpapierbörse / free trade

Original content of: Medigene AG, transmitted by news aktuell

More stories: Medigene AG
More stories: Medigene AG